Sleep and Dementia; Predicting Parkinson’s Progression; Aducanumab’s ICER Price

News

The latest about sleep deprivation and dementia: The Washington Post interviews researchers about recent studies.

The American Academy of Sleep Medicine coordinated an initiative with the American Academy of Neurology and others to respond to the Agency for Healthcare Research and Quality’s draft assessment questioning CPAP’s long-term clinical benefits.

Repetitive head hits caused chronic synaptic adaptation and long-term cognitive impairment in mice. (Nature Communications)

In 2020, 24.6% of teens reported at least one diagnosed concussion in their lifetime, up from 19.5% in 2016. (JAMA)

Researchers identified genetic drivers and a polygenic score for predicting progression to dementia in Parkinson’s disease. (Nature Genetics)

About one in four people with Parkinson’s had enlarged fasting gallbladder volume, a small study showed. (Parkinsonism & Related Disorders)

Persistent disability risk dropped by 50% to 70% in pediatric-onset multiple sclerosis in recent years, paralleled by greater and longer use of disease-modifying therapies. (JAMA Neurology)

Diffusion-weighted imaging measures of brain connectivity predicted cognitive recovery in stroke patients, but offered no added value over conventional predictors. (Stroke)

Entorhinal hypometabolism assessed by fluorodeoxyglucose PET (FDG-PET) was a strong and independent predictor of subsequent cognitive decline in preclinical Alzheimer’s disease. (Neurology)

Tau forms oligomeric complexes on microtubules that are distinct from tau aggregates, single-molecule localization microscopy showed. (PNAS)

Price watchdog ICER slammed aducanumab for insufficient evidence of health benefit, suggesting cost-effectiveness thresholds as low as $2,500 a year. The FDA decision about the investigational Alzheimer’s treatment is expected in June.

  • Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Products You May Like

Articles You May Like

Not all experts are ready to vaccinate kids against Covid
WHO says delta is becoming the dominant Covid variant globally
Evidently Cochrane Blog: Living with Long Term Conditions Part 2
High junk food consumption in childhood increases risk of unhealthy body fat by early adulthood
Neighborhood disadvantage related to increased COVID-19 infections and mortality

Leave a Reply

Your email address will not be published. Required fields are marked *